Saxenda

Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1
Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1
Fierce Pharma
Novo Nordisk
Saxenda
Latin America
obesity
Flag link:
Novo Nordisk: Why The Diabetes Giant Will Continue To Grow
Novo Nordisk: Why The Diabetes Giant Will Continue To Grow
Seeking Alpha
Novo Nordisk
diabetes
Tresiba
Saxenda
Victoza
Flag link:
Novo Nordisk: Make-And-Take Strategy For The Obesity Drug Market
Novo Nordisk: Make-And-Take Strategy For The Obesity Drug Market
Seeking Alpha
Novo Nordisk
obesity
Saxenda
Flag link:
Novo Nordisk: Has This Company Solved The Anti-Obesity Sector Woes?
Novo Nordisk: Has This Company Solved The Anti-Obesity Sector Woes?
Seeking Alpha
Novo Nordisk
Saxenda
obesity
Canada
Flag link:
Novo Nordisk Launches Obesity Medication In Canada - How Did That Happen?
Novo Nordisk Launches Obesity Medication In Canada - How Did That Happen?
Seeking Alpha
Novo Nordisk
obesity
Saxenda
Canada
drug launches
Flag link:
Novo Nordisk executive fuels firm's new obesity fight
Novo Nordisk executive fuels firm's new obesity fight
Medical Marketing and Media
Novo Nordisk
obesity
Saxenda
Jesper Høiland
Flag link:
What Novo Nordisk's Entry Into The Obesity Space Means To The Sector
What Novo Nordisk's Entry Into The Obesity Space Means To The Sector
Seeking Alpha
Novo Nordisk
obesity
Saxenda
Flag link:
Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month
Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month
Fierce Pharma
Novo Nordisk
Saxenda
obesity
Flag link:
Novo Nordisk Quietly Becoming Big Player In Obesity Space
Novo Nordisk Quietly Becoming Big Player In Obesity Space
Seeking Alpha
Novo Nordisk
obesity
Saxenda
Flag link:
How Novo Nordisk plans to keep its eyes on the diabetes prize
How Novo Nordisk plans to keep its eyes on the diabetes prize
BioPharma Dive
Novo Nordisk
diabetes
Saxenda
Flag link:
Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep Expectations Realistic
Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep Expectations Realistic
Seeking Alpha
Novo Nordisk
Saxenda
drug launches
Flag link:
Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales
Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales
Fierce Pharma
Novo Nordisk
Saxenda
drug reps
Flag link:
FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
5 Obesity Stocks Investors Are Watching
5 Obesity Stocks Investors Are Watching
Yahoo/Benzinga
obesity
Orexigen
Contrave
Arena Pharmaceuticals
Belviq
APD334
Vivus
Qsymia
EnteroMedics
devices
Maestro System
Novo Nordisk
Saxenda
Flag link:
Novo Nordisk to promote drug to treat obesity in United States
Novo Nordisk to promote drug to treat obesity in United States
Yahoo/Reuters
Novo Nordisk
obesity
Saxenda
Flag link:
4 Potential Blockbuster Drugs The FDA Just Approved
4 Potential Blockbuster Drugs The FDA Just Approved
Investors.com
Bristol-Myers Squibb
Opdivo
Merck
Cubist Pharmaceuticals
Zerbaxa
AstraZeneca
Lynparza
Novo Nordisk
Saxenda
Flag link:
FDA approves Novo Nordisk's Saxenda, an injectable weight-loss treatment
FDA approves Novo Nordisk's Saxenda, an injectable weight-loss treatment
Yahoo/AP
Novo Nordisk
FDA
Saxenda
obesity
liraglutide
Flag link:
Are obesity drugs nearing a breakout? Novo, Takeda think so
Are obesity drugs nearing a breakout? Novo, Takeda think so
Fierce Pharma
Novo Nordisk
Takeda
obesity
Saxenda
Flag link:
Novo May Add Hundreds to R&D Staff for Obesity Medicines
Novo May Add Hundreds to R&D Staff for Obesity Medicines
Bloomberg
Novo Nordisk
R&D
hirings
Saxenda
obesity
Flag link:
Novo’s Weight-Loss Shot Wins Backing of U.S. Advisers
Novo’s Weight-Loss Shot Wins Backing of U.S. Advisers
Bloomberg
Novo Nordisk
FDA
obesity
vaccines
Saxenda
liraglutide
Flag link: